Skip to main content

Table 3 Therapeutic studies on blood flow in CADASIL

From: Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) as a model of small vessel disease: update on clinical, diagnostic, and management aspects

Drug Effect
Acetazolamide Related to an increase of cerebral perfusion evaluated by perfusion MRI [156], transcranial Doppler sonography [157] and Tc-99 m extracellular domain brain perfusion SPECT [158, 159]
Atorvastatin No effects on cerebral blood flow [160], tested with transcranial Doppler
L-arginine Induced-vasoreactivity [161], tested with transcranial Doppler
Sapropterin (200–400 mg bid in 24 months) Final results for the primary end-point (mean difference in reactive hyperemia index) were not significant for any improvement of peripheral vasoreactivity [162]
Novel molecular therapeutic target (as stem cell factor and granulocyte-colony stimulating factor) Ongoing [163]